BEDFORD, Mass.--(BUSINESS WIRE)--Ocular Therapeutixâ„¢, Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for ...
Conventional thinking among ophthalmologists has been to tell their patients with glaucoma to sleep with their head elevated, but doing so may contribute to the progression of the eye disorder and, in ...
Iyuzeh is a preservative-free prostaglandin F2α analogue. The Food and Drug Administration (FDA) has approved Iyuzeh ™ (latanoprost ophthalmic solution) 0.005% for the reduction of elevated ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...
Glaucoma is the most common cause of blindness in older adults. The condition involves damage to the eye’s optic nerve, and without treatment, it can lead to vision loss or blindness. Glaucoma is a ...
No, glaucoma isn’t cancer. It’s a chronic eye condition that may lead to blurry vision and vision loss due to damage to the optic nerve. Glaucoma results from the pressure caused by fluid accumulation ...
High eye pressure does not always cause glaucoma, but it is a significant risk factor. Lowering high eye pressure may reduce the risk, although glaucoma can also occur in people with typical eye ...
Omlonti is a relatively selective EP2 receptor agonist designed to increase aqueous humor drainage through the conventional (or trabecular) and uveoscleral outflow pathways. The Food and Drug ...
Please provide your email address to receive an email when new articles are posted on . The FDA approved Iyuzeh for the reduction of elevated IOP in patients with open-angle glaucoma or ocular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results